Fujisawa H, Nishimura T, Kimura K
Research Laboratories, Nippon Shinyaku Co., Ltd., Kyoto, Japan.
J Toxicol Sci. 1995 Dec;20 Suppl 2:341-8. doi: 10.2131/jts.20.supplementii_341.
An antigenicity study of montirelin hydrate (NS-3), a new drug for the treatment of disturbance of consciousness, was conducted in Hartley guinea pigs. Animals were sensitized twice by subcutaneous injections of montirelin hydrate in combination with Freund's complete adjuvant and twice by intramuscular injections of montirelin hydrate alone. Montirelin hydrate was found to be negative in the homologous passive cutaneous anaphylaxis test carried out with sera from the sensitized guinea pigs. Negative results were also obtained in the active cutaneous anaphylaxis test and the active systemic anaphylaxis test in guinea pigs sensitized with montilerin hydrate. These results show that montirelin hydrate has no antigenicity under the present experimental conditions.
对用于治疗意识障碍的新药水合蒙特瑞林（NS - 3）进行了抗原性研究，实验对象为哈特利豚鼠。通过皮下注射水合蒙特瑞林与弗氏完全佐剂联合用药使动物致敏两次，以及单独肌肉注射水合蒙特瑞林使动物致敏两次。在用致敏豚鼠的血清进行的同源被动皮肤过敏试验中，发现水合蒙特瑞林呈阴性。在用蒙特瑞林水合物致敏的豚鼠进行的主动皮肤过敏试验和主动全身过敏试验中也得到了阴性结果。这些结果表明，在目前的实验条件下水合蒙特瑞林没有抗原性。
